Mon. 26 Feb 2024, 9:02am ET
Benzinga
Biotech, News, Contracts, General
Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to include SNAP-CAR NK cells, has potential to impact various autoimmune diseases in addition to oncology indications.